LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202216581 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Mi Bai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, State Key Laboratory of Reproductive Medicine, Children's Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Protease La, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST ¦ National Key Research and Development Program of China, Nanjing Science and Technology Development Outstanding Youth Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Mitochondria comprise the central metabolic hub of cells and their imbalance plays a pathogenic role in chronic kidney disease (CKD). Here, we studied Lon protease 1 (LONP1), a major mitochondrial protease, as its role in CKD pathogenesis is unclear. LONP1 expression was decreased in human patients and mice with CKD, and tubular‐specific Lonp1 overexpression mitigated renal injury and mitochondrial dysfunction in two different models of CKD, but these outcomes were aggravated by Lonp1 deletion. These results were confirmed in renal tubular epithelial cells in vitro . Mechanistically, LONP1 downregulation caused mitochondrial accumulation of the LONP1 substrate, 3‐hydroxy‐3‐methylglutaryl‐CoA synthase 2 (HMGCS2), which disrupted mitochondrial function and further accelerated CKD progression. Finally, computer‐aided virtual screening was performed, which identified a novel LONP1 activator. Pharmacologically, the LONP1 activator attenuated renal fibrosis and mitochondrial dysfunction. Collectively, these results imply that LONP1 is a promising therapeutic target for treating CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, State Key Laboratory of Reproductive Medicine, Children's Hospital of Nanjing Medical University, Nanjing, China.
- Jiangsu Key Laboratory of Pediatrics, Nanjing Medical University, Nanjing, China.
- Nanjing Key Laboratory of Pediatrics, Children's Hospital of Nanjing Medical University, Nanjing, China.
- Key Laboratory of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China.
- Renal Division, Peking University First Hospital, Beijing, China.
ORCID-Profile: Mengqiu Wu, Jia He, Lin Wang, Li Yang, Zhanjun Jia, Aihua Zhang
Förderung
- MOST ¦ National Key Research and Development Program of China
- Nanjing Science and Technology Development Outstanding Youth Project
- National Natural Science Foundation of China
Zitieren
APA
Bai, M., Wu, M., Jiang, M., He, J., Deng, X., Xu, S., Fan, J., Miao, M., Wang, T., Li, Y., Yu, X., Wang, L., Zhang, Y., Huang, S., Yang, L., Jia, Z., & Zhang, A. (2023). LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216581
Vancouver
Bai M, Wu M, Jiang M, He J, Deng X, Xu S, et al. LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202216581
BibTeX
@article{Bai2023,
author = {Bai, Mi and Wu, Mengqiu and Jiang, Mingzhu and He, Jia and Deng, Xu and Xu, Shuang and Fan, Jiaojiao and Miao, Mengqiu and Wang, Ting and Li, Yuting and Yu, Xiaowen and Wang, Lin and Zhang, Yue and Huang, Songming and Yang, Li and Jia, Zhanjun and Zhang, Aihua},
title = {LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202216581}
}
EUVIMED